In the last decade, new forms of cancer therapy have been developed to stimulate the body's immune system against cancer, called "immunotherapy." These are in contrast to traditional cancer therapies such as radiation, chemotherapy and surgery which are frequently ineffective and can be significantly harmful to patients. Most recently, "Checkpoint Blockade" and "CAR-T Cell" therapies, which both use the "T cells" of the immune system, have had great success, with Science magazine calling Cancer Immunotherapy the "Breakthrough of the Year" in 2013.Learn More +
Do you have a story you'd like to share?
Follow our research and tell us what it means to you.
Tyler Jacks and his laboratory at MIT began research on NK cells six years ago, thinking they could leverage the work of T cells and target cancer in and of themselves. He teamed up with Dr. David Raulet, one of the world's leading researchers on NK cells, and Bill Haney, a friend and tech entrepreneur, to start Dragonfly.Our Story +